Last reviewed · How we verify
Fluticasone propionate inhaled aerosol
At a glance
| Generic name | Fluticasone propionate inhaled aerosol |
|---|---|
| Sponsor | Xijing Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma (PHASE2)
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- Efficacy of Intermittent Tiotropium in Early Childhood Wheezing (PHASE4)
- Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year (PHASE4)
- Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (PHASE2)
- To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone propionate inhaled aerosol CI brief — competitive landscape report
- Fluticasone propionate inhaled aerosol updates RSS · CI watch RSS
- Xijing Hospital portfolio CI